Compare ABR & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABR | MLTX |
|---|---|---|
| Founded | 2003 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2003 | 2020 |
| Metric | ABR | MLTX |
|---|---|---|
| Price | $5.03 | $15.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $9.90 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 4.1M | 1.3M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 15.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.73 | $5.95 |
| 52 Week High | $12.58 | $62.75 |
| Indicator | ABR | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 36.32 |
| Support Level | $4.94 | $14.84 |
| Resistance Level | $5.45 | $19.24 |
| Average True Range (ATR) | 0.15 | 0.73 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 25.64 | 13.78 |
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.